دورية أكاديمية
Dose escalation in brachytherapy for cervical cancer: impact on (or increased need for) MRI-guided plan optimisation.
| العنوان: | Dose escalation in brachytherapy for cervical cancer: impact on (or increased need for) MRI-guided plan optimisation. |
|---|---|
| المؤلفون: | Paton AM; Radiotherapy Physics Unit, Bristol Haematology and Oncology Centre, University Hospitals Bristol NHS Foundation Trust, UK., Chalmers KE, Coomber H, Cameron AL |
| المصدر: | The British journal of radiology [Br J Radiol] 2012 Dec; Vol. 85 (1020), pp. e1249-55. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0373125 Publication Model: Print Cited Medium: Internet ISSN: 1748-880X (Electronic) Linking ISSN: 00071285 NLM ISO Abbreviation: Br J Radiol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: January 2024- : [Oxford] : Oxford University Press Original Publication: London, British Institute of Radiology. |
| مواضيع طبية MeSH: | Brachytherapy/*methods , Carcinoma/*radiotherapy , Magnetic Resonance Imaging, Interventional/*methods , Uterine Cervical Neoplasms/*radiotherapy, Adult ; Aged ; Dose-Response Relationship, Radiation ; Female ; Humans ; Middle Aged ; Organs at Risk/radiation effects ; Radiography, Interventional ; Radiotherapy Dosage ; Radiotherapy Planning, Computer-Assisted/methods ; Retrospective Studies ; Tomography, X-Ray Computed ; Treatment Outcome |
| مستخلص: | Objective: The aim of this study was to assess the impact of dose escalation on the proportion of patients requiring MR image-guided optimisation rather than standard Manchester-based CT-guided planning, and the level of escalation achievable. Methods: 30 patients with cervical cancer treated with external beam radiotherapy and image-guided brachytherapy (IGBT) had MR images acquired at the first fraction of IGBT. Gross tumour volume and high-risk clinical target volume (HR CTV) were contoured and treatment plans retrospectively produced for a range of total 2-Gy equivalent (EQD2) prescription doses from 66 Gy(α/β=10) to 90 Gy(α/β=10) (HR CTV D90). Standard Manchester system-style plans were produced, prescribed to point A and then optimised where necessary with the aim of delivering at least the prescription dose to the HR CTV D90 while respecting organ-at-risk (OAR) tolerances. Results: Increasing the total EQD2 from 66 Gy(α/β=10) to 90 Gy(α/β=10) increased the number of plans requiring optimisation from 13.3% to 90%. After optimisation, the number of plans achieving the prescription dose ranged from 93.3% (66 Gy(α/β=10)) to 63.3% (90 Gy(α/β=10)) with the mean ± standard deviation for HR CTV D90 EQD2 from 78.4 ± 12.4 Gy(α/β=10) (66 Gy(α/β=10)) to 94.1 ± 19.9 Gy(α/β=10) (90 Gy(α/β=10)). Conclusion: As doses are escalated, the need for non-standard optimised planning increases, while benefits in terms of increased target doses actually achieved diminish. The maximum achievable target dose is ultimately limited by proximity of OARs. Advances in Knowledge: This work represents a guide for other centres in determining the highest practicable prescription doses while considering patient throughput and maintaining acceptable OAR doses. |
| References: | Brachytherapy. 2012 Jan-Feb;11(1):47-52. (PMID: 22265437) Radiother Oncol. 2006 Jan;78(1):67-77. (PMID: 16403584) Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):307-17. (PMID: 9607346) Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):934-9. (PMID: 16199322) Clin Oncol (R Coll Radiol). 2009 Apr;21(3):175-82. (PMID: 19101130) Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):901-11. (PMID: 15936576) Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):250-5. (PMID: 21183288) Radiother Oncol. 1994 Jun;31(3):240-7. (PMID: 8066207) Radiother Oncol. 2006 Dec;81(3):269-75. (PMID: 17126938) Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):56-63. (PMID: 19289267) Radiother Oncol. 2007 May;83(2):148-55. (PMID: 17531904) Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):653-7. (PMID: 21345618) Radiother Oncol. 2011 Jul;100(1):116-23. (PMID: 21821305) Int J Radiat Oncol Biol Phys. 1991 Sep;21(4):885-98. (PMID: 1917616) Radiother Oncol. 2005 Mar;74(3):235-45. (PMID: 15763303) Gynecol Oncol. 1993 Jun;49(3):311-7. (PMID: 8314532) Radiother Oncol. 2010 Feb;94(2):173-80. (PMID: 20138380) |
| تواريخ الأحداث: | Date Created: 20121124 Date Completed: 20130125 Latest Revision: 20211021 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC3611731 |
| DOI: | 10.1259/bjr/30377872 |
| PMID: | 23175490 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1748-880X |
|---|---|
| DOI: | 10.1259/bjr/30377872 |